Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel

Can J Neurol Sci. 2016 Jul;43(4):472-85. doi: 10.1017/cjn.2016.37. Epub 2016 Apr 8.

Abstract

Pompe disease is a lysosomal storage disorder caused by a deficiency of the enzyme acid alpha-glucosidase. Patients have skeletal muscle and respiratory weakness with or without cardiomyopathy. The objective of our review was to systematically evaluate the quality of evidence from the literature to formulate evidence-based guidelines for the diagnosis and management of patients with Pompe disease. The literature review was conducted using published literature, clinical trials, cohort studies and systematic reviews. Cardinal treatment decisions produced seven management guidelines and were assigned a GRADE classification based on the quality of evidence in the published literature. In addition, six recommendations were made based on best clinical practices but with insufficient data to form a guideline. Studying outcomes in rare diseases is challenging due to the small number of patients, but this is in particular the reason why we believe that informed treatment decisions need to consider the quality of the evidence.

Keywords: Pompe disease; guidelines; review.

Publication types

  • Review

MeSH terms

  • Canada
  • Disease Management*
  • Evidence-Based Practice / methods
  • Glycogen Storage Disease Type II / diagnosis*
  • Glycogen Storage Disease Type II / therapy*
  • Humans